靶向G9a/GLP促进多发性骨髓瘤自噬相关凋亡并增强蛋白酶体抑制剂疗效
多发性骨髓瘤(MM)中组蛋白甲基转移酶G9a高表达与不良预后相关。使用G9a/GLP抑制剂BIX01294和UNC0638可诱导MM细胞G1期阻滞和凋亡,并通过抑制mTOR/4EBP1通路和降低c-MYC促进自噬相关凋亡。G9a/GLP靶向还增敏硼替佐米和卡非佐米,在5TGM1小鼠中延迟肿瘤生长并延长生存。
要点
- G9a高表达与初诊和复发MM患者更差预后相关。
- G9a/GLP抑制剂诱导MM细胞G1期阻滞和凋亡,降低原代MM细胞活力。
- G9a/GLP靶向增敏蛋白酶体抑制剂,在体内延迟肿瘤生长并延长生存。
核心结论
- G9a/GLP通过阻断基础自噬和维持高c-MYC水平支持MM细胞生长和生存。
- 靶向G9a/GLP是改善高G9a/GLP水平患者蛋白酶体抑制剂治疗的潜在策略。
研究设计与样本
- 研究使用MM细胞系、原代MM细胞和5TGM1小鼠模型。
- 使用特异性G9a/GLP抑制剂BIX01294和UNC0638进行体外和体内实验。
主要发现
- 高G9a RNA水平与初诊和复发MM患者更差疾病结局相关。
- BIX01294和UNC0638诱导MM细胞系G1期阻滞和凋亡,并降低原代MM细胞活力。
- G9a/GLP靶向通过失活mTOR/4EBP1通路和降低c-MYC水平促进自噬相关凋亡。
- G9a/GLP靶向通过进一步降低mTOR信号和c-MYC水平并激活p-38和SAPK/JNK信号增敏硼替佐米和卡非佐米。
- 5TGM1小鼠中BIX01294延迟体内MM肿瘤生长,与硼替佐米联用进一步减少肿瘤负荷并显著延长生存。
临床怎么用
- G9a/GLP靶向可能作为增敏蛋白酶体抑制剂的策略,尤其适用于高G9a/GLP水平的MM患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multiple myeloma (MM) is an (epi)genetic highly heterogeneous plasma cell malignancy that remains mostly incurable. Deregulated expression and/or genetic defects in epigenetic-modifying enzymes contribute to high-risk disease and MM progression. Overexpression of the histone methyltransferase G9a was reported in several cancers, including MM, correlating with disease progression, metastasis, and poor prognosis. However, the exact role of G9a and its interaction partner G9a-like protein (GLP) in MM biology and the underlying mechanisms of action remain poorly understood. Here, we report that high G9a RNA levels are associated with a worse disease outcome in newly diagnosed and relapsed MM patients. G9a/GLP targeting using the specific G9a/GLP inhibitors BIX01294 and UNC0638 induces a G1-phase arrest and apoptosis in MM cell lines and reduces primary MM cell viability. Mechanistic studies revealed that G9a/GLP targeting promotes autophagy-associated apoptosis by inactivating the mTOR/4EBP1 pathway and reducing c-MYC levels. Moreover, genes deregulated by G9a/GLP targeting are associated with repressive histone marks. G9a/GLP targeting sensitizes MM cells to the proteasome inhibitors (PIs) bortezomib and carfilzomib, by (further) reducing mTOR signaling and c-MYC levels and activating p-38 and SAPK/JNK signaling. Therapeutic treatment of 5TGM1 mice with BIX01294 delayed in vivo MM tumor growth, and cotreatment with bortezomib resulted in a further reduction in tumor burden and a significantly prolonged survival. In conclusion, we provide evidence that the histone methyltransferases G9a/GLP support MM cell growth and survival by blocking basal autophagy and sustaining high c-MYC levels. G9a/GLP targeting represents a promising strategy to improve PI-based treatment in patients with high G9a/GLP levels.
引用
- De Smedt E, Devin J, Muylaert C, et al. G9a/GLP targeting in MM promotes autophagy-associated apoptosis and boosts proteasome inhibitor-mediated cell death. Blood Adv. 2021. PMID: 33938943. doi:10.1182/bloodadvances.2020003217
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。